Actinium Pharmaceuticals

 Fact Sheet  Research Report

Actinium Pharmaceuticals, Inc. is a New York - based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha - emitting actinium - 225 and bismuth - 213 and certain beta emitting radiopharmaceuticals in conjunct ion with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™ - B is indicated for preparing patients for hematopoietic stem cell transplant (HSCT) , commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, m ulticenter Phase 3 clinical study of Iomab™ - B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The C ompany’s second program, Actimab - A, is continuing its clinical dev elopment in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single - arm multicenter trial.

Find a broker to begin trading ATNM now

Investment HighlightsValue Proposition
Company Name Actinium Pharmaceuticals
Market/Symbol NYSE MKT: ATNM
Recent Price
Market Cap $56.41M
Avg. Daily Vol. (3m) 490,951
Price/Book N/A
Price/Cash Flow N/A
As of Jul. 25, 2017
*Source: QuoteMedia

Begin trading ATNM

 Find Broker



Investment Highlights

  • Only potential cure for many blood cancers is a bone marrow transplant, but vast majority of patients over 50 are ineligible (up to 90%); Iomab-B has demonstrated ability to successfully prepare these patients for the procedure
  • Iomab-B survival rates: 1+ years - about 30%, 2+ years - about 20% . Current standard of care survival rates: 1+ years - about 10%, 2+ years - less than 2%
  • Estimated worldwide market potential of $4.1 billion for Iomab-B

  • 2nd generation therapy; 1st generation therapy is Bismab-A
  • Bismab-A had excellent Phase 2 results (trials showed 4x higher median survival in patients ineligible for approved chemotherapy); Actimab-A's Phase 1 results were superior to Bismab-A's comparable Phase 1 results, in addition to being simpler and cheaper
  • Estimated worldwide market potential of $920 million for AML

  • Technology platform developed with its largest shareholder Sloan-Kettering has strong IP
  • Potential therapies at pre-clinical stage include Actimab-B (bone marrow transplant), Actimab-C (colon cancer), and Actimab-P (prostate cancer)

  • New President and CEO Kaushik J. Dave hired in September 2013; previous position was Executive Vice President of Product Development at Antares Pharma, whose market cap rose from approximately $40 million to over $500 million during his tenure
  • Active involvement in drug development by luminaries from world-class institutions such as MD Anderson, Johns Hopkins, Fred Hutchison Cancer Center, U. Penn, Sloan Kettering

Value Proposition

ATNM has two potentially blockbuster therapies that have had excellent clinical trial results, with efficacy shown to be superior to the currently available treatment options none of which are FDA approved. These therapies have a lower overall cost of treatment, providing economic benefits to hospitals and ensuring that the Company can generate strong gross profits from its drugs. ATNM’s platform is highly scalable with multiple therapies in preclinical development and potential to improve upon existing biotech drugs. The median market cap of oncology companies with a lead therapy in phase 3 trials is $444 million. ATNM’s market cap is only $286 million, which provides considerable upside, especially when considering the excellent clinical trial results from its two therapies and the long-term scalability of its Alpha Particle Immunotherapy platform technology (APIT).

Actinium Pharmaceuticals Latest News

Ask the CEO

Meet The Board of Directors

Kaushik J. Dave

C. David Nicholson


Sandesh Seth

Richard l. Steinhart


Sergio Traversa

Interim CFO

Meet The Management Team

Kaushik J. Dave


Dragan Cicic


Sergio Traversa

Interim CFO

Corey Sohmer

Vice President of Finance and Business Development

Betsy C. King

Quality Assurance and Regulatory Affairs

Gaylord King


ATNM Research

Median Survival of 9.1 months compared to 2-5 months in sAML patients. In the interim analysis, 9 patients with intermediate or poor risk cytogenetics and a median age of 76 were exhibited… Read More

Nov. 06, 2014

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Historical SEC Filings

Receive ATNM Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market